[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"China-Japan Friendship Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":590},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,83,0,25,[9,44,74,100,126,149,170,199,222,249,271,292,312,332,351,373,393,409,432,452,478,501,520,546,570],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100649580","exploration-of-appropriate-bis-range-and-propofol-effect-site-concentration-during-total-intravenous-anesthesia-with-concomitant-adjuvants-100649580",false,"NCT07736352","Exploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants.","A Prospective, Randomized Study to Determine the Appropriate Bispectral Index Range and Propofol Effect-Site Concentration During Total Intravenous Anesthesia Combined With Midazolam, Dexmedetomidine or Esketamine.","Inclusion Criteria:\n\n* Age 18 to 65 years\n* American Society of Anesthesiologists (ASA) physical status I or II\n* Body Mass Index (BMI) 18 to 30 kg\u002Fm²\n* Scheduled for elective unilateral total knee replacement surgery\n* Willing to participate in the study and signed informed consent form, and able to comply with the intervention and assessment procedures\n\nExclusion Criteria:\n\n* History of neurological disorders\n* Cognitive dysfunction assessed by the Mini-Cog scale\n* History of antipsychotic or sedative medication use in the past 4 weeks\n* Poorly controlled or untreated hypertension\n* Sinus bradycardia, cardiac conduction block, or severe heart failure\n* Acute angle-closure glaucoma\n* Allergic to intravenous anesthetics\n* Hearing impairment, could not cooperate in intervention and evaluation\n* Contraindications to tourniquet use on the upper arm","ALL","18 Years","65 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine the appropriate Bispectral Index (BIS) range and propofol effect-site concentration required to maintain adequate anesthesia depth during total intravenous anesthesia (TIVA) combined with midazolam, dexmedetomidine, or esketamine in patients undergoing unilateral knee replacement surgery. The main questions it aims to answer are:\n\n1. What are the appropriate BIS range and propofol effect-site concentration for maintaining adequate anesthesia depth when combined with each of the three medications (midazolam, dexmedetomidine, or esketamine) during TIVA?\n2. How these combination regimens affect the quality of recovery and postoperative pain in patients？\n\nParticipants will:\n\n1. Receive one of four anesthesia regimens during surgery: propofol alone, propofol combined with midazolam, dexmedetomidine, or esketamine.\n2. Undergo a stepwise reduction of propofol effect-site concentration towards the end of surgery.\n3. Have their consciousness assessed using the isolated forearm technique, while BIS, EEG signals, and vital signs are continuously monitored throughout the procedure.\n4. Have their recovery quality and postoperative pain assessed after surgery.",[28,29,30,31],"Knee Osteoarthritis","Replacement, Knee","Elective Surgical Patients","ASA Class I\u002FII Patients","NOT_YET_RECRUITING","2026-07-26",{"date":35,"type":36},"2026-07-30","ACTUAL",{"date":38,"type":22},"2026-08-01",{"date":40,"type":22},"2027-07-31",{"name":42,"class":43},"China-Japan Friendship Hospital","OTHER",{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100649390","bariatric-surgery-combined-with-glp-1ra-a-multicenter-study-100649390","NCT07732738","Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.","The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Obesity: A Prospective, Multicenter Cohort Study","BS-GLP","Inclusion Criteria:\n\n1. Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).\n2. obesity:BMI ≥27.5 kg\u002Fm².\n3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.\n4. Age range: 16-70 years (inclusive).\n5. Informed consent: Willing participation with documented consent.\n\nExclusion Criteria:\n\n1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.\n2. Prior bariatric surgery: History of any metabolic\u002Fbariatric surgical procedure.\n3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).\n4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications.\n5. Significant comorbidities:\n\nAdvanced hepatic\u002Frenal dysfunction (Child-Pugh C or eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²) Active malignancy (except non-melanoma skin cancers) Autoimmune disorders requiring immunosuppression Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression)","16 Years","70 Years",{"count":55,"type":22},400,[25],"Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits.\n\nGiven the lack of multi-regional validation in China's diverse population, this multicenter study aims to confirm the real-world effectiveness and generalizability of bariatric surgery plus GLP-1RA across distinct regional cohorts.",[59],"Obesity",[61,62,63,64],"obesity","Glucagon-Like Peptide-1 Receptor Agonist","Bariatric Surgery","multicenter","RECRUITING",{"date":67,"type":36},"2026-07-29",{"date":69,"type":36},"2025-01-01",{"date":71,"type":22},"2027-12-30",{"name":42,"class":43},7,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100642940","phase-1-research-on-the-efficacy-and-mechanism-of-shouhui-tongbian-capsules-in-treating-postoperative-constipation-of-benign-anal-and-rectal-diseases-based-on-gut-microbiota-analysis-100642940","NCT07648394","Research on the Efficacy and Mechanism of Shouhui Tongbian Capsules in Treating Postoperative Constipation of Benign Anal and Rectal Diseases Based on Gut Microbiota Analysis","Inclusion Criteria:\n\nSurgical indication for a benign anorectal disease, including hemorrhoids or anal fistula Diagnosis of postoperative constipation after benign anorectal surgery Postoperative constipation symptoms such as difficulty defecating, reduced bowel movement frequency, hard or lumpy stools, incomplete evacuation, anorectal obstruction, or abdominal distension Ability to tolerate the planned anorectal surgical procedure without related contraindications Consciousness and ability to cooperate with treatment, follow-up, and questionnaire assessments Written informed consent provided by the participant or legally authorized representative Age 18 to 75 years, inclusive\n\nExclusion Criteria:\n\nSevere systemic disease, including serious psychiatric or immune disorders Severe infection Malignant tumor Severe organic disease of a major organ, including the heart, liver, or kidneys Pregnancy Breastfeeding Postpartum period Coagulation dysfunction Other anorectal disease that may affect outcome assessment Known allergy to either study treatment or any treatment component Any other condition considered by the investigators to make participation unsuitable","75 Years",{"count":82,"type":22},120,[84,85],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate whether Shouhui Tongbian Capsule can improve postoperative constipation in adults aged 18 to 75 years after surgery for benign anorectal diseases, including hemorrhoids and anal fistula. The clinical trial will also evaluate the safety of Shouhui Tongbian Capsule and explore associations between treatment effects and changes in gut microbiota, metabolic profiles, and inflammatory indicators.\n\nThe main questions are:\n\nDoes Shouhui Tongbian Capsule improve constipation symptoms after benign anorectal surgery? Does Shouhui Tongbian Capsule reduce postoperative and defecation-related pain? Does Shouhui Tongbian Capsule improve quality of life and anorectal function? What adverse events occur during treatment? Are clinical improvements associated with changes in gut microbiota, metabolic profiles, or inflammatory indicators?\n\nResearchers will compare Shouhui Tongbian Capsule with lactulose to evaluate differences in efficacy and safety for postoperative constipation.\n\nParticipants will:\n\nReceive either Shouhui Tongbian Capsule three times daily or lactulose once daily for 14 days Complete assessments of constipation symptoms, pain, quality of life, and anorectal function Provide stool and blood samples before treatment and on Day 14 Attend assessments during treatment and approximately 1 month after surgery Report adverse events and other medical problems during participation",[88,89,90,91],"Intestinal Flora","Anorectal Diseases","Surgery","Constipation","2026-07-21",{"date":94,"type":36},"2026-07-22",{"date":38,"type":22},{"date":97,"type":22},"2027-06-30",{"name":42,"class":43},1,{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":99},"100645771","the-effects-of-midazolam-dexmedetomidine-and-esketamine-on-bispectral-index-and-raw-electroencephalogram-in-patients-under-propofol-remifentanil-baseline-anesthesia-100645771","NCT07699523","The Effects of Midazolam, Dexmedetomidine, and Esketamine on Bispectral Index and Raw Electroencephalogram in Patients Under Propofol-Remifentanil Baseline Anesthesia","Inclusion Criteria:\n\n1. ASA physical status I-II;\n2. BMI 18-28 kg\u002Fm²;\n3. Scheduled for elective laparoscopic cholecystectomy, with an expected surgical duration from skin incision to completion of wound closure of ≥45 min;\n4. Planned to receive propofol-remifentanil total intravenous anesthesia, with routine intraoperative BIS monitoring and simultaneous acquisition of raw EEG signals;\n5. Voluntarily agrees to participate in this study, has signed the informed consent form, and is able to cooperate with the intervention and assessment procedures.\n\nExclusion Criteria:\n\n1. A confirmed history of psychiatric or neurological disorders, or use of antipsychotics, antidepressants, benzodiazepines, or other sedative-hypnotic drugs within 4 weeks before surgery;\n2. Cognitive impairment identified by Mini-Cog screening;\n3. Poorly controlled or untreated hypertension, sinus bradycardia, or severe cardiac conduction block;\n4. Acute angle-closure glaucoma;\n5. Known allergy to any required anesthetic drug;\n6. Difficulty in electrode placement or any condition that may interfere with EEG monitoring.",{"count":82,"type":22},[25],"This prospective, single-center, randomized interventional study aims to investigate the effects of commonly used adjunct anesthetic drugs on the Bispectral Index (BIS) and electroencephalographic (EEG) activity during total intravenous anesthesia.\n\nBIS monitoring is widely used to estimate the depth of anesthesia. However, previous studies suggest that certain anesthetic drugs, particularly dexmedetomidine and esketamine, may alter BIS values independently of the patient's actual level of consciousness. As a result, BIS readings may not always accurately reflect anesthetic depth when multiple drugs are administered together.\n\nAdult patients undergoing elective laparoscopic cholecystectomy under standardized propofol-remifentanil anesthesia will be randomly assigned to receive one of the following adjunct drugs: midazolam, dexmedetomidine, esketamine, or no additional study drug (control group). Continuous BIS values and raw EEG signals will be recorded throughout the study period.\n\nThe primary objective is to compare changes in BIS values among different adjunct anesthetic drugs under otherwise similar anesthetic conditions. The study will also explore corresponding EEG characteristics associated with these changes. The findings are expected to improve understanding of drug-related differences in processed EEG monitoring and provide data for future development of more accurate anesthesia depth assessment methods.",[110,111],"Depth of Anesthesia Monitoring","BIS-EEG",[113,114,115,116,117,118],"Bispectral Index","Electroencephalography","Midazolam","Dexmedetomidine","Esketamine","Total Intravenous Anesthesia","2026-07-08",{"date":121,"type":36},"2026-07-13",{"date":123,"type":22},"2026-06-30",{"date":71,"type":22},{"name":42,"class":43},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":99},"100600469","endobronchial-silicone-valve-for-patients-with-emphysema-100600469","NCT07097896","Endobronchial Silicone Valve for Patients With Emphysema","Bronchoscopic Lung Volume Reduction With Endobronchial Silicone Valve for Patients With Emphysema: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Clinical and radiological evidence of emphysema\n* Nonsmoking for 4 months prior to screening interview\n* BMI less than 35 kg\u002Fm2\n* Stable on current medication regimen\n* Forced expiratory volume in one second (FEV1) between 15% and 45% of predicted value\n* Residual Volume less than 175% predicted (determined by body plethysmography)\n* Little or no collateral ventilation (CV-) as determined using the Chartis System\n\nExclusion Criteria:\n\n* Had two or more hospitalizations over the last year for a COPD exacerbation\n* Had two or more hospitalizations over the last year for pneumonia\n* Had a prior lung transplant, lung volume reduction surgery, bullectomy or lobectomy\n* Had a heart attack or congestive heart failure within the last 6 months\n* Have heart arrhythmia\n* Is alpha-1 antitrypsin deficient",{"count":134,"type":22},147,[25],"The purpose of this research is to evaluate the efficacy and safety of endobronchial silicone valve in patients with severe emphysema.",[138],"Emphysema",[140,138,141],"Endobronchial Lung Volume Reduction","Chronic Obstructive Pulmonary Disease","2026-07-06",{"date":119,"type":36},{"date":145,"type":36},"2025-07-08",{"date":147,"type":22},"2027-07",{"name":42,"class":43},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100646865","effect-of-oral-astaxanthin-formula-on-pulmonary-rehabilitation-in-patients-with-copd-100646865","NCT07684391","Effect of Oral Astaxanthin Formula on Pulmonary Rehabilitation in Patients With COPD","Effect of Oral Astaxanthin Formula Supplement on Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: a Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Patients who met the GOLD diagnostic criteria for stage II-IV COPD\n* Patients who met the indications for pulmonary rehabilitation training: mMRC score\n\n  * 3 or self-reported decline in physical function.\n\nExclusion Criteria:\n\n* Hypoxemia (resting partial pressure of oxygen \\\u003C 60mmHg or oxygen saturation \\\u003C 88%) or patients requiring continuous oxygen therapy or with any contraindications to exercise testing (refer to the American Society of Thoracic Surgeons\u002FAmerican College of Chest Physicians exercise testing guidelines).\n* Using oral glucocorticoids\n* Long-term oxygen therapy\n* Participated in a supervised exercise program within the past 12 months\n* History of other pulmonary diseases, including pneumoconiosis, bronchiectasis, tuberculosis, primary pulmonary hypertension, pulmonary embolism, interstitial lung disease\n* Skeletal, neuromuscular, cardiovascular, or metabolic disorders that limit the participant's ability to exercise actively or that involve muscle activity, such as cancer, diabetes, muscle weakness, etc.","80 Years",{"count":158,"type":22},140,[25],"The goal of this clinical trial is to investigate whether an astaxanthin-based dietary supplement combined with a pulmonary rehabilitation training program could improve exercise capacity in patients with COPD. The main questions it aims to answer are:\n\n• whether an astaxanthin-based dietary supplement combined with a pulmonary rehabilitation training program could improve 6MWD in patients with COPD.\n\nThe drug administration group will receive:\n\n* Two capsules of astaxanthin formula supplement daily for 8 weeks.\n* Pulmonary rehabilitation training: a total of 8 weeks, 2-3 times a week.\n\nThe control group will receive a total of 8-week pulmonary rehabilitation training, 2-3 times a week.\n\nThe investigators will compare the drug administration group and the control group to see if the difference between the 2 groups reaches a minimal clinically important difference.",[162],"COPD","2026-06-29",{"date":142,"type":36},{"date":166,"type":22},"2026-07-01",{"date":168,"type":22},"2026-12-31",{"name":42,"class":43},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":99},"100641194","efficacy-of-pha130-hemoadsorption-on-protein-bound-uremic-toxins-and-quality-of-life-in-kidney-failure-100641194","NCT07656168","Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure","A Prospective, Multicenter, Randomized Controlled Trial of HAHD With pHA130 Cartridge vs. Conventional High-Flux HD for Clearance of Protein-Bound Uremic Toxins and Quality of Life Improvement in Kidney Failure.","PHOENIX","Inclusion Criteria:\n\n* Age \\> 18 years.\n* On maintenance hemodialysis for \\> 3 months.\n* Receiving hemodialysis 3 times per week, 4 hours per session.\n* Standard Kt\u002FV ≥ 1.2.\n* Voluntarily participates and provides written informed consent.\n\nExclusion Criteria:\n\n* Known allergy to the dialyzer or hemoperfusion device.\n* Platelet count \\\u003C 60×10⁹\u002FL.\n* Serum albumin \\\u003C 30 g\u002FL.\n* 24-hour urine output \\> 200 ml.\n* Inability to achieve a blood flow rate ≥ 200 ml\u002Fmin.\n* Coagulation disorders, severe bleeding tendency, or active bleeding.\n* Pre-dialysis systolic blood pressure \\\u003C 90 mmHg or diastolic blood pressure \\\u003C 60 mmHg.\n* Active malignancy.\n* Active infection, or severe, critical illness of cardiac, pulmonary, hepatic, or nervous systems.\n* Planned living-donor kidney transplant within the next 6 months.\n* Current participation in another interventional clinical study, or participation within the past 3 months in an interventional study that may interfere with the present study (e.g., fecal microbiota transplantation); or use of intestinal microecological regulators such as probiotics.\n* History of unstable angina, myocardial infarction, malignant arrhythmia, cardiac or peripheral vascular surgery, or cerebrovascular accident within the past 8 weeks.",{"count":21,"type":22},[25],"Patients on maintenance hemodialysis (MHD) face a high risk of cardiovascular mortality and reduced quality of life. Conventional high-flux hemodialysis (HD) is the standard of care but has limited efficacy in clearing middle-molecular and protein-bound uremic toxins (PBUTs). The accumulation of these toxins is associated with adverse long-term outcomes.\n\nThis study evaluates the efficacy and safety of the pHA130 hemoadsorption cartridge, which utilizes a modified resin for enhanced PBUT adsorption, when combined with hemodialysis (HAHD). This is a prospective, open-label, multi-center, randomized controlled trial involving 100 MHD patients. Participants will be randomized 1:1 to either the HAHD group (receiving one HAHD session using the pHA130 cartridge and two standard HD sessions weekly) or the Control group (receiving three standard HD sessions weekly).\n\nThe primary objective is to assess the reduction in serum indoxyl sulfate (IS) and p-cresol sulfate (PCS) levels from baseline to 12 months. Secondary objectives include evaluating changes in quality of life (KDQoL-SF, MMSE), the progression of coronary artery calcification (CAC), the incidence of major adverse cardiovascular events (MACEs), all-cause mortality, and safety profiles. This trial aims to determine if integrating long-term HAHD therapy can optimize blood purification strategies for the MHD population.",[182,183],"ESRD (End-Stage Renal Disease)","Maintenance Hemodialysis",[185,186,187,188,189,190],"Hemoadsorption","Protein-Bound Uremic Toxins","Indoxyl Sulfate","p-Cresyl Sulfate","Cardiovascular Events","Quality of Life","2026-06-22",{"date":193,"type":36},"2026-06-25",{"date":195,"type":36},"2026-06-01",{"date":197,"type":22},"2028-08",{"name":42,"class":43},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":4},"100601768","dual-function-semirigid-thoracoscopy-versus-rigid-thoracoscopy-for-the-diagnosis-of-pleural-disease-100601768","NCT07114783","Dual-function Semirigid Thoracoscopy Versus Rigid Thoracoscopy for the Diagnosis of Pleural Disease","Dual-function Semirigid Thoracoscopy Versus Rigid Thoracoscopy for the Diagnosis of Pleural Disease: a Randomised Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Patients with unilateral pleural effusion of unclear aetiology after less invasive means of diagnosis;\n3. Fully informed of the purpose and method of the study, agreed to participate in the study, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with PaO2\u002FFiO2 \\\u003C300;\n2. Patients with a tendency for uncontrolled bleeding, unstable cardiovascular status or severe heart failure;\n3. Patients with complete pleural symphysis, where it was not possible to create a pneumothorax, were excluded subsequently;\n4. Patients with refractory cough;\n5. Patients with Eastern Cooperative Oncology Group performance status 4;\n6. Patients did not agree to participate in this study;\n7. Participation in other studies within three months without withdrawal or termination will affect the observation of this study.",{"count":207,"type":22},92,[25],"Medical thoracoscopy (rigid and semirigid) is an effective, safe method for diagnosing and managing pleural diseases. Rigid thoracoscopy demonstrates superior overall diagnostic yield compared to semirigid techniques (flexible forceps\u002Fcryobiopsy) due to its ability to obtain larger, deeper biopsies with rigid forceps. However, diagnostic rates become similar when biopsies are successfully obtained.\n\nLimitations of rigid thoracoscopy include restricted maneuverability (especially in posterior\u002Fmediastinal areas), increased procedural pain from leveraging against ribs and larger trocars, higher sedation requirements, and a steep learning curve for pulmonologists.\n\nTo address these issues, a novel dual-function semirigid thoracoscope (UE FET-680, China) was developed. Its straight working channel accommodates standard rigid biopsy forceps, potentially matching rigid thoracoscopy's diagnostic yield while improving usability. This randomized trial will compare the efficacy and safety of this new device versus conventional rigid thoracoscopy in undiagnosed exudative pleural effusions.",[211],"Pleural Effusion Disorder",[213,214],"Medical Thoracoscopy","Pleural Disease","2026-06-16",{"date":191,"type":36},{"date":218,"type":22},"2026-08",{"date":220,"type":22},"2027-12",{"name":42,"class":43},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":99},"100642984","glp-1-therapy-after-bariatric-surgery-in-chinese-patients-with-obesity-100642984","NCT07633639","GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity","The Efficacy and Safety of Adjuvant GLP-1 Receptor Agonist Therapy Following Metabolic Bariatric Surgery in Chinese Patients With Obesity: A Prospective, Monocentric, Stratified Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).\n2. obesity:BMI ≥30 kg\u002Fm².\n3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.\n4. Age range: 18-60 years (inclusive).\n5. Informed consent: Willing participation with documented consent.\n\nExclusion Criteria:\n\n1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.\n2. Prior bariatric surgery: History of any metabolic\u002Fbariatric surgical procedure.\n3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).\n4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications.\n5. Significant comorbidities:\n\n5.1Advanced hepatic\u002Frenal dysfunction (Child-Pugh C or eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²). 5.2Active malignancy (except non-melanoma skin cancers). 5.3Autoimmune disorders requiring immunosuppression. 5.4Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression).","60 Years",{"count":231,"type":22},200,[25],"Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.",[59],[61,236,237,238,239,240],"Glucagon-Like Peptide-1 Receptor Agonists","Metabolic Bariatric Surgery","Semaglutide","Mazdutide","Tirzepatide","2026-06-04",{"date":243,"type":36},"2026-06-08",{"date":245,"type":36},"2026-05-01",{"date":247,"type":22},"2028-05-01",{"name":42,"class":43},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":99},"100624230","a-study-on-the-efficacy-and-safety-of-jak-inhibitors-versus-calcineurin-inhibitors-as-initial-therapy-for-interstitial-lung-disease-associated-with-antisynthetase-syndrome-100624230","NCT07406932","A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","JAKCNIASSILD","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Meet the 2017 EULAR\u002FACR diagnostic criteria for Anti-synthetase Syndrome (ASS).\n* Presence of Interstitial Lung Disease (ILD) confirmed by High-Resolution Computed Tomography (HRCT).\n* Active disease requiring initiation or intensification of immunosuppressive therapy, with no prior use of glucocorticoids, immunosuppressants, or biologics.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Diagnosis of Rapidly Progressive ILD (RP-ILD), defined as worsening dyspnea within 1 month and PaO2\u002FFiO2 ratio \\\u003C 250 mmHg.\n* Active uncontrolled severe infection, malignancy, or major organ failure.\n* Pregnancy or lactation.\n* Contraindications to the study drugs.\n* Concurrent use of other immunosuppressants or biologics.",{"count":257,"type":22},80,[25],"This study is a prospective investigation comparing the efficacy and safety of Janus kinase inhibitors versus calcineurin inhibitors as initial therapy for interstitial lung disease associated with antisynthetase syndrome. The goal is to determine which treatment is more effective at improving lung function and preventing disease progression, while comparing their safety profiles. The findings will help provide clearer treatment guidance for doctors and patients.",[261,262],"Antisynthetase Syndrome","Interstitial Lung Disease (ILD)","2026-05-31",{"date":265,"type":36},"2026-06-03",{"date":267,"type":22},"2026-05-18",{"date":269,"type":22},"2027-07-01",{"name":42,"class":43},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":99},"100637826","clinical-trial-study-on-the-improved-new-method-of-acupotomy-for-as-100637826","NCT07578220","Clinical Trial Study on the Improved New Method of Acupotomy for AS","Clinical Trial Study on the Improved New Method of Acupotomy for Ankylosing Spondylitis","Inclusion Criteria:\n\n1. Meeting the 1984 revised New York criteria or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis\n2. Age 18-75 years\n3. BASDAI ≥4\n4. Signed informed consent form\n\nExclusion Criteria:\n\n1. Presence of autoimmune diseases other than the studied condition\n2. Complete spinal ankylosis or spinal deformity\n3. Pregnant or lactating women\n4. Comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, malignant tumors, or coagulation disorders\n5. Patients unable to comply with data collection due to mental, linguistic, or similar factors\n6. Patients with psoriatic arthritis, reactive arthritis, or inflammatory bowel disease-associated spondyloarthritis",{"count":279,"type":22},60,[25],"This study employs a randomized controlled trial methodology to systematically evaluate the efficacy and safety of a modified acupotomy technique in the treatment of ankylosing spondylitis. Through ultrasound-guided localization, the operative sites are assessed to clarify the improvement effect of the modified acupotomy on disease activity in AS patients. The aim is to enhance the clinical outcomes of AS, provide evidence-based medical support for acupotomy treatment of AS, and improve the diagnosis and treatment standards for the condition.",[283],"Ankylosing Spondylitis","2026-05-11",{"date":286,"type":36},"2026-05-13",{"date":288,"type":36},"2025-12-02",{"date":290,"type":22},"2029-06-30",{"name":42,"class":43},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":299,"targetDuration":301,"studyType":302,"phases":4,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100636686","frailty-and-intraoperative-hypoxemia-risk-in-elderly-ercp-patients-100636686","NCT07568912","Frailty and Intraoperative Hypoxemia Risk in Elderly ERCP Patients","The Predictive Value of Frailty for Intraoperative Hypoxemia in Elderly Patients Undergoing ERCP: A Two-Directional Cohort Study and Predictive Model Construction","Inclusion Criteria:\n\n1. Age 65 years or older\n2. Elective endoscopic retrograde cholangiopancreatography (ERCP) under anesthesia sedation\n3. American Society of Anesthesiologists (ASA) physical status II-IV\n4. Expected procedure duration less than 60 minutes\n5. Available and complete intraoperative pulse oximetry (SpO₂) monitoring data\n\nExclusion Criteria:\n\n1. Emergency ERCP\n2. Severe anemia (hemoglobin \\\u003C 60 g\u002FL) or conditions interfering with accurate 3. SpO₂ measurement\n\n4\\. Pre-existing severe respiratory insufficiency requiring long-term oxygen therapy 5. Unstable hemodynamics requiring continuous vasopressor infusion Impaired consciousness, delirium, or cognitive dysfunction that prevents reliable frailty assessment",{"count":300,"type":22},701,"3 Months","OBSERVATIONAL","Intraoperative hypoxemia is a common and serious complication during monitored anesthesia care for elective endoscopic retrograde cholangiopancreatography (ERCP), especially in older adults. Frail patients have reduced physiologic reserve and are at increased risk of life-threatening events including unplanned intubation, hemodynamic collapse, and hypoxic brain injury. However, the independent relationship between frailty and intraoperative hypoxemia during sedated ERCP remains poorly defined, and no validated risk prediction model exists for this high-risk population. This single-center, dual-cohort study will be conducted at China-Japan Friendship Hospital to evaluate whether preoperative frailty can predict intraoperative hypoxemia in patients aged 65 years and older undergoing elective ERCP. Frailty will be assessed primarily using the Frailty Index (FI), with secondary screening by the Modified Frailty Index-11 (mFI-11), Edmonton Frail Scale (EFS), Clinical Frailty Scale (CFS), FRAIL scale, and Fried phenotype. The primary outcome is intraoperative hypoxemia, defined as SpO₂ \\\u003C 90% for 5 seconds or longer. In the retrospective phase (n = 313), investigators will identify risk factors and develop a preliminary prediction model. In the prospective phase (n = 388), the model will be validated, refined, and internally tested for discrimination, calibration, and clinical utility. This study aims to establish frailty as a reliable preoperative risk marker and provide a clinically practical prediction tool to support risk stratification, personalized sedation strategies, and perioperative safety in elderly patients undergoing ERCP.",[305],"Hypoxemia",{"date":307,"type":36},"2026-05-06",{"date":195,"type":22},{"date":310,"type":22},"2028-12-31",{"name":42,"class":43},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":319,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":99},"100635710","evaluating-the-efficacy-and-short-term-prognosis-of-integrated-traditional-chinese-and-western-medicine-for-ankylosing-spondylitisas-a-protocol-for-a-cohort-study-100635710","NCT07556224","Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis(AS): A Protocol for a Cohort Study","Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis(AS): A Protocol for a Prospective Multicenter Cohort Study","Inclusion Criteria:\n\n* fulfill the 1984 modified New York criteria for ankylosing spondylitis or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis\n* age between 18 and 75 years\n* sign informed consent.\n\nExclusion Criteria:\n\n* diagnosis of other autoimmune diseases besides the disease under investigation (e.g., rheumatoid arthritis, Sjögren's syndrome, erythema nodosum, myositis, etc.)\n* pregnancy or lactation\n* comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or malignancy\n* spondyloarthritis related to enteropathic arthritis, psoriatic arthritis, or reactive arthritis\n* unable to provide data due to mental, language, or similar factors.",{"count":320,"type":22},790,"This study is a multicenter, prospective cohort study designed to systematically evaluate the clinical efficacy of integrated Traditional Chinese and Western Medicine on short-term functional improvement in patients with ankylosing spondylitis, with the Bath Ankylosing Spondylitis Functional Index (BASFI) at 6 months of treatment as the primary outcome measure.",[323],"Ankylosing Spondylitis (AS)","2026-04-22",{"date":326,"type":36},"2026-04-29",{"date":328,"type":36},"2026-01-19",{"date":330,"type":22},"2028-06-30",{"name":42,"class":43},{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":50,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":229,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":343,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":99},"100618841","phase-1-bariatric-surgery-combined-with-glp-1-receptor-agonists-study-100618841","NCT07336862","Bariatric Surgery Combined With GLP-1 Receptor Agonists Study","The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Severe Obesity: A Prospective, Multicenter Cohort Study","Inclusion Criteria:\n\n1. Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG)\n2. obesity:BMI ≥35 kg\u002Fm²\n3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria\n4. Age range: 18-60 years (inclusive)\n5. Informed consent: Willing participation with documented consent\n\nExclusion Criteria:\n\n1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively\n2. Prior bariatric surgery: History of any metabolic\u002Fbariatric surgical procedure\n3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak)\n4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications\n5. Significant comorbidities:\n\n   * Advanced hepatic\u002Frenal dysfunction (Child-Pugh C or eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n   * Active malignancy (except non-melanoma skin cancers)\n   * Autoimmune disorders requiring immunosuppression\n   * Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression)",{"count":231,"type":22},[84,85],"Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.",[59],[61,236,63],"2026-04-20",{"date":346,"type":36},"2026-04-23",{"date":348,"type":36},"2024-01-01",{"date":220,"type":22},{"name":42,"class":43},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":99},"100573097","confocal-laser-endomicroscopy-guided-medical-thoracoscopy-for-the-diagnosis-of-pleural-disease-100573097","NCT06741839","Confocal Laser Endomicroscopy Guided Medical Thoracoscopy for the Diagnosis of Pleural Disease","Efficacy and Safety of Confocal Laser Endomicroscopy Guided Medical Thoracoscopy for the Diagnosis of Pleural Disease: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Evidence of exudative pleural effusion in which a specific diagnosis could not be determined using clinical, radiological, laboratory, or cytological examinations\n* Willingness to participate in the study and undergo an invasive procedure.;\n\nExclusion Criteria:\n\n* Pleural thickening or pleural-based mass without pleural effusion on radiologic examination;\n* Hemodynamic instability;\n* Presence of parapneumonic effusion;\n* Any contraindication to pleural biopsy or semirigid thoracoscopy;\n* Participation in other studies within three months without withdrawal or termination.",{"count":359,"type":22},158,[25],"A prospective multicenter randomized controlled trial was conducted to evaluate the efficacy and safety of thoracoscopic biopsy guided by confocal optical real-time microscopic imaging (nCLE) in the diagnosis of fibrinal pleurisy of unknown etiology. Patients with fibrinous pleurisy of unknown etiology who were to undergo thoracoscopic pleural biopsy were enrolled and informed consent was signed. Subjects were randomized to either the nCLE guided biopsy Group (Group A) or the visual biopsy group (Group B) according to the randomization table (1:1 ratio). nCLE was used to probe the benign and malignant status of pleural lesions, compare the consistency of random pathological biopsy or nCLE guided biopsy with histopathological results, compare whether nCLE guided biopsy can reduce the number of thoracoscopic biopsies, and follow up short-term postoperative complications to evaluate its safety.",[363,364],"Pleural Diseases","Pleural Effusion","2026-04-11",{"date":367,"type":36},"2026-04-15",{"date":369,"type":36},"2025-03-11",{"date":371,"type":22},"2027-05",{"name":42,"class":43},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":99},"100581002","the-disease-progression-of-chinese-axial-spondyloarthritis-in-a-real-word-cohort-study-100581002","NCT06844643","The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study","DPCASPA","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Diagnosis of axial spondyloarthritis (axSpA) according to the Assessment of Spondyloarthritis International Society (ASAS) classification criteria\n\nExclusion Criteria:\n\n* Presence of severe, unstable medical conditions that may interfere with the study assessments, including but not limited to:\n\nEnd-stage renal disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²) Severe cardiovascular disease Active malignancy or malignancy requiring ongoing treatment\n\n* Current diagnosis of schizophrenia, other psychotic disorders, severe cognitive impairment, or epilepsy with recurrent uncontrolled seizures, which, in the opinion of the investigator, may impair the ability to provide informed consent or comply with follow-up visits.\n* Pregnant or lactating women",{"count":381,"type":22},2250,"An observational, ambispective cohort to learn about the disease progression of axial spondyloarthritis (axSpA) according to the changes from baseline in measures of disease activity, function, and imaging.",[384,323],"Axial Spondyloarthritis","2026-04-10",{"date":387,"type":36},"2026-04-13",{"date":389,"type":36},"2025-03-01",{"date":391,"type":22},"2030-12-01",{"name":42,"class":43},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":399,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":408,"locationsCount":99},"100632137","integrated-traditional-chinese-and-western-medicine-for-ankylosing-spondylitis-as-a-cohort-study-protocol-focusing-on-spondyloarthritis-research-consortium-of-canada-sparcc-scoring-system-100632137","NCT07509775","Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System","Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis: A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System",{"count":400,"type":22},210,"This study is a multicentre, ambidirectional, observational cohort study. The ambidirectional design incorporates both the collection of retrospective data from the three years prior to enrolment, and a prospective follow-up period of up to two years. The study is designed to evaluate the long-term effects of Integrated Medicine on radiographic progression in patients diagnosed with Ankylosing spondylitis (AS).",[323],"2026-04-04",{"date":405,"type":36},"2026-04-09",{"date":328,"type":36},{"date":330,"type":22},{"name":42,"class":43},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":416,"sex":17,"minAge":18,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":429,"leadSponsor":431,"locationsCount":4},"100630078","effects-of-baduanjin-exercise-on-improving-health-in-sedentary-young-and-middle-aged-adults-100630078","NCT07482995","Effects of Baduanjin Exercise on Improving Health in Sedentary Young and Middle-Aged Adults","A Multicenter, Randomized Controlled Trial to Evaluate the Efficacy and Mechanisms of Baduanjin on Improving Health Outcomes in Sedentary Young and Middle-Aged Adults","Inclusion Criteria:\n\n* Adults aged 18 to 59 years\n* Sedentary and physically inactive, defined as: (a) self-reported sitting time ≥ 8 hours per day, AND (b) not meeting the World Health Organization (WHO) recommended level of physical activity ( engaging in \\\u003C 150 minutes of moderate-to-vigorous intensity physical activity per week, assessed by the International Physical Activity Questionnaire \\[IPAQ\\])\n* In good general health as self-reported, and free from any known diseases\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Contraindications to cardiopulmonary exercise testing\n* Currently participating in, or planning to participate within the next 3 months, in any other structured exercise or behavioral intervention program\n* Pregnancy, lactation, or planning to become pregnant during the study period\n* Inability to understand or comply with the study procedures",true,"59 Years",{"count":419,"type":22},208,[25],"The goal of this clinical trial is to learn if a 12-week Baduanjin exercise program can improve health in sedentary young and middle-aged adults. The main questions it aims to answer are:\n\n1. Does the Baduanjin program improve participants' cardiorespiratory fitness (measured as peak oxygen uptake)?\n2. Does it improve their body composition, muscle strength, balance, and flexibility?\n3. Does it reduce their daily sitting time?\n\nResearchers will compare the Baduanjin training group to a health education control group to see if Baduanjin is more effective in improving these health outcomes.\n\nParticipants will:\n\n1. Be randomly assigned to one of the two groups.\n2. If in the Baduanjin group, attend supervised group sessions and practice at home for 12 weeks.\n3. Complete a series of assessments at the beginning, middle, and end of the study, including fitness tests, body measurements, and questionnaires.",[423,424],"Sedentary Lifestyle","Behavioral Intervention","2026-03-16",{"date":427,"type":36},"2026-03-19",{"date":385,"type":22},{"date":430,"type":22},"2027-08-10",{"name":42,"class":43},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":451,"locationsCount":99},"100628279","diagnostic-performance-and-safety-of-endobronchial-ultrasound-guided-transbronchial-mediastinal-cryobiopsy-in-diagnosing-tuberculous-mediastinal-lymphadenitis-a-randomised-controlled-trial-100628279","NCT07459569","Diagnostic Performance and Safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy in Diagnosing Tuberculous Mediastinal Lymphadenitis: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Age 18 years or older;\n* Presence of unexplained mediastinal lymphadenopathy (short-axis diameter ≥1 cm on chest computed tomography) with clinical suspicion of tuberculosis;\n* Completion of routine pre-procedural evaluations including blood tests (complete blood count, coagulation profile), electrocardiogram, and chest CT;\n* Absence of contraindications for EBUS-TBNA or EBUS-TBMC procedures;\n* Provision of written informed consent after being fully informed of the study purpose and procedures.\n\nExclusion Criteria:\n\n* Known allergy to lidocaine or midazolam;\n* Presence of bronchial artery penetration into the target lesion or high risk of bleeding as detected by contrast-enhanced CT or EBUS Doppler mode prior to the procedure;\n* Unstable angina, congestive heart failure, or severe bronchial asthma;\n* Evidence of significant liquefaction necrosis in the target mediastinal lymph node on pre-procedural CT or EBUS;\n* Patient refusal to participate in the study;\n* Participation in another clinical trial within the past three months that may interfere with the outcomes of this study;\n* Any other condition that, in the opinion of the investigator, makes the patient unsuitable for study participation",{"count":439,"type":22},108,[25],"The goal of this clinical trial is to compare the diagnostic efficacy and safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy (EBUS-TBMC) versus standard EBUS-guided Transbronchial Needle Aspiration (EBUS-TBNA) in adult patients with suspected mediastinal lymph node tuberculosis. The main questions it aims to answer are:\n\nDoes EBUS-TBMC provide a superior diagnostic yield for detecting granulomatous inflammation compared to EBUS-TBNA in the same target lymph node? Does the cryopreservation process affect the viability of Mycobacterium tuberculosis for culture, and does the larger tissue sample obtained via EBUS-TBMC enhance the sensitivity of molecular tests such as Xpert MTB\u002FRIF? Is the safety profile of EBUS-TBMC, particularly regarding bleeding complications, comparable to that of EBUS-TBNA in this patient population? Researchers will compare the two biopsy techniques using a paired design within the same patient to see if EBUS-TBMC results in higher rates of positive pathology, microbiology, and molecular diagnoses.\n\nParticipants will:\n\nUndergo both EBUS-TBNA and EBUS-TBMC procedures on the same mediastinal lymph node during a single bronchoscopy session, with the order of procedures randomized.\n\nProvide blood and tissue samples for comprehensive testing, including histology, mycobacterial culture, and Xpert MTB\u002FRIF assay.\n\nComplete short-term (within 2 hours post-procedure) and 7-day follow-up assessments to monitor for any adverse events.\n\nParticipate in a 6-month clinical follow-up to establish a final diagnosis, which will serve as the reference standard for evaluating the diagnostic tests.",[443,444],"Tuberculosis","Mediastinal and Hilar Lymph Node Enlargement","2026-03-05",{"date":447,"type":36},"2026-03-09",{"date":449,"type":22},"2026-05",{"date":371,"type":22},{"name":42,"class":43},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":416,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":4},"100626806","evaluation-of-an-ar-assisted-system-for-standardizing-spirometry-100626806","NCT07440420","Evaluation of an AR-Assisted System for Standardizing Spirometry","Evaluation of an Augmented Reality Assisted System for Standardizing Spirometry (AR-SPIRO Trial): Protocol for a Two-phase Validation and Randomized Controlled Trial","Inclusion Criteria:\n\nPhase 1\n\n* Age ≥ 18 years.\n* Able to provide written informed consent.\n\nPhase 2\n\n* Age ≥ 40 years.\n* Cumulative smoking history of ≥10 pack-years or history of biomass fuel exposure for ≥10 years.\n* Able to provide written informed consent.\n\nExclusion Criteria (both two phase):\n\n* Presence of absolute or relative contraindications to spirometry.\n* Current pregnancy.\n* Severe vision or hearing impairments that preclude the effective use of Augmented Reality (AR) glasses.",{"count":460,"type":22},710,[25],"Spirometry is the gold-standard tool for diagnosing Chronic Obstructive Pulmonary Disease (COPD). However, its implementation in primary care is often limited by a shortage of qualified technicians and inconsistent testing quality. This study will use Augmented Reality (AR) glasses to provide real-time interaction and guidance to participants during spirometry. It will be designed as a two-phase study to evaluate the technical validity and clinical effectiveness of AR-assisted spirometry (AR-SPIRO) system.",[141],[465,466,141,467,468,469],"Augmented Reality","Spirometry","Primary Health Care","Digital Health","Study Protocol","2026-02-26",{"date":472,"type":36},"2026-02-27",{"date":474,"type":22},"2026-03",{"date":476,"type":22},"2026-06",{"name":42,"class":43},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":99},"100625206","ultrasounic-elastography-guided-pleural-biopsy-followed-by-as-needed-medical-thoracoscopic-pleural-biopsy-versus-immediate-medical-thoracoscopic-pleural-biopsy-for-the-diagnosis-of-pleural-effusion-100625206","NCT07419620","Ultrasounic Elastography-guided Pleural Biopsy Followed by As-needed Medical Thoracoscopic Pleural Biopsy Versus Immediate Medical Thoracoscopic Pleural Biopsy for the Diagnosis of Pleural Effusion","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Patients with exudative pleural effusion of unknown origin;\n3. Patients with negative pleural fluid cytology results;\n4. Patients who had not undergone pleural biopsy before enrolment.\n\nExclusion Criteria:\n\n1. Significantly bleeding risk, including uncorrectable coagulopathy (such as INR \\>1.5, platelet count \\\u003C50×109 \u002FL) or the need for ongoing anticoagulant\u002Fantiplatelet therapy that cannot be safely paused;\n2. Hemodynamic instability;\n3. Refractory hypoxemia despite supplemental oxygen;\n4. Any severe concurrent illness or cardiopulmonary compromise that, in the investigator's judgment, makes either procedural sedation (for thoracoscopy) or a bedside biopsy (for UEPB) unsafe;\n5. Pleural effusion conclusively identified as a transudate;\n6. Pregnancy or lactation;\n7. Any condition that, in the investigator's judgment, would compromise protocol compliance or follow-up.",{"count":485,"type":22},420,[25],"Brief Summary\n\nThe goal of this clinical trial is to determine whether an initial diagnostic approach using ultrasound elastography-guided pleural biopsy (UEPB) is non-inferior to immediate medical thoracoscopic pleural biopsy in terms of diagnostic yield for obtaining a definitive histopathological diagnosis in patients with exudative pleural effusion of unclear etiology.\n\nThe main questions it aims to answer are:\n\nIs the step-up strategy (UEPB first, reserving thoracoscopy for non-diagnostic cases) non-inferior to immediate medical thoracoscopy in diagnostic yield?\n\nDoes the step-up strategy provide advantages in safety, patient tolerance, hospital stay, and cost-effectiveness compared to immediate thoracoscopy?\n\nResearchers will compare a step-up strategy (initial UEPB, followed by medical thoracoscopy if UEPB is non-diagnostic) versus immediate medical thoracoscopic pleural biopsy to see if the step-up approach achieves comparable diagnostic accuracy while potentially reducing procedure-related burden and healthcare resource use.\n\nParticipants will:\n\nBe randomly assigned in a 1:1 ratio to either the step-up strategy arm or the immediate medical thoracoscopy arm.\n\nIf assigned to the step-up arm: undergo UEPB under local anesthesia; if the biopsy is non-diagnostic, proceed to semi-rigid medical thoracoscopy.\n\nIf assigned to the immediate thoracoscopy arm: undergo semi-rigid medical thoracoscopic pleural biopsy as the initial and sole diagnostic procedure.\n\nProvide tissue samples for histopathological, immunohistochemical, and molecular analyses as clinically indicated.\n\nComplete short-term follow-up at 7 days post-procedure (by telephone or clinic visit) to monitor adverse events and symptom recovery.\n\nIf initially diagnosed with non-specific benign disease or remain undiagnosed, complete a long-term follow-up at 12 months to establish a final diagnosis.",[211],[490,491,492],"Pleural biopsy","Ultrasoinc elastography","Semi-rigid thoracoscopy","2026-02-12",{"date":495,"type":36},"2026-02-19",{"date":497,"type":22},"2026-04",{"date":499,"type":22},"2028-04",{"name":42,"class":43},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":23,"phases":508,"briefSummary":509,"conditions":510,"keywords":511,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":519,"locationsCount":99},"100623975","ventilation-perfusion-discrepancy-index-versus-conventional-anatomic-physiologic-assessment-for-target-lung-lobe-selection-in-endobronchial-valve-placement-a-multicenter-randomised-controlled-trial-100623975","NCT07403617","Ventilation-Perfusion Discrepancy Index Versus Conventional Anatomic-Physiologic Assessment for Target Lung Lobe Selection in Endobronchial Valve Placement: A Multicenter, Randomised Controlled Trial",{"count":507,"type":22},285,[25],"The goal of this clinical trial is to learn if a Ventilation-Perfusion Discrepancy Index (VQDI)-guided strategy for selecting the target lung lobe can improve outcomes compared to the standard strategy in patients with severe emphysema undergoing bronchoscopic lung volume reduction with endobronchial valves (EBVs).\n\nThe main question it aims to answer is:\n\n· Does selecting the target lobe based on the lowest VQDI (indicating the worst functional mismatch) lead to a higher rate of successful treatment response at 6 months compared to selecting the lobe based on the worst destruction on CT scan?\n\nIf there is a comparison group: Researchers will compare the VQDI-guided selection group to the conventional CT\u002FChartis-guided selection group to see which strategy results in more patients achieving significant improvement in both lung function and reduction in the size of the treated lobe.\n\nParticipants will:\n\n* Undergo standard clinical assessments (lung function tests, CT scan, exercise test) and an additional V\u002FQ SPECT\u002FCT scan to calculate the VQDI.\n* Have their collateral ventilation status checked using the Chartis system during bronchoscopy.\n* Be randomly assigned to one of the two target lobe selection strategies.\n* Receive EBV placement in the selected lobe.\n* Attend follow-up visits at 1, 3, 6, and 12 months after the procedure for check-ups, repeated lung function tests, questionnaires, and CT scans to assess their response to treatment.",[138],[140,512,138,141],"Ventilation-Perfusion Discrepancy Index","2026-02-05",{"date":515,"type":36},"2026-02-11",{"date":497,"type":22},{"date":518,"type":22},"2028-10",{"name":42,"class":43},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":527,"targetDuration":4,"studyType":23,"phases":529,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":99},"100623103","early-phase-1-efficacy-and-mechanisms-of-macitentan-for-non-coronary-obstructive-angina-100623103","NCT07392281","Efficacy and Mechanisms of Macitentan for Non-Coronary Obstructive Angina","MAC-NOCA","Inclusion Criteria:\n\n* Age 18-75 years old.\n* With typical angina symptoms.\n* Excluding obstructive coronary lesions (coronary stenosis ≤50% or FFR ≥0.8) by CAG.\n* Coronary microcirculatory function was confirmed via pressure wire-based thermodilution technique.（Patients were classified into subtypes based on coronary microcirculatory function indices: 1) Type I: CFR ≥ 2.5 and IMR \\\u003C 25; 2) Type II: CFR ≥ 2.5 and IMR ≥ 25; 3) Type III: CFR \\\u003C 2.5 and IMR \\\u003C 25; 4) Type IV: CFR \\\u003C 2.5 and IMR ≥ 25.）\n* Sign a written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* History of heart attack within the last 90 days.\n* Severe heart disease (e.g., moderate to severe heart failure, severe heart valve disease).\n* Severe renal impairment (GFR \\\u003C30 ml\u002Fmin\u002F1.73m2).\n* Severe liver disease (Child-Pugh class C).\n* Moderately severe anaemia (haemoglobin concentration \\\u003C90 g\u002FL).\n* Participation in another drug intervention trial study within the last 90 days.",{"count":528,"type":22},40,[530],"EARLY_PHASE1","Angina with non-obstructive coronary arteries (ANOCA) is highly prevalent, impairing quality of life and independently associated with cardiovascular events, yet effective treatments are lacking. The endothelin-1 (ET-1)-endothelin receptor (ETR) system is pivotal in ANOCA pathogenesis. Preclinical studies show that ETR blockade or pericyte-specific knockout of ETA receptor improves coronary microcirculatory function in models of myocardial ischemia-reperfusion and diabetes. Clinical evidence indicates ETR antagonists can enhance microvascular endothelial function and myocardial perfusion in ANOCA patients. However, prior studies diagnosed ANOCA based only on symptoms and angiography without precise microvascular functional assessment. Early ETR antagonists also showed frequent adverse effects (e.g., edema, headache), reducing treatment satisfaction. To address this, the investigators will conduct an open-label, single-center, single-arm trial using invasive coronary microcirculatory function testing to accurately phenotype ANOCA and assess microvascular changes. Patients on standard therapy will receive macitentan-a novel ETR antagonist with improved vasodilatory efficacy and safety-to evaluate its effects on coronary microcirculatory function, angina symptoms, and adverse events. Additionally, the investigators will perform multi-omics profiling (proteomics, transcriptomics, metabolomics) on patient blood samples to identify molecular signatures linked to ANOCA subtypes and treatment response, providing evidence for precision intervention strategies in ANOCA.",[533],"Non-Coronary Obstructive Angina",[533,535,536,537],"Coronary microvscular dysfunction","Macitentan","Endothelin-receptor antagonists","2026-02-04",{"date":540,"type":36},"2026-02-06",{"date":542,"type":36},"2025-09-01",{"date":544,"type":22},"2027-08-31",{"name":42,"class":43},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":553,"enrollmentInfo":554,"targetDuration":4,"studyType":23,"phases":555,"briefSummary":556,"conditions":557,"keywords":559,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":99},"100619079","early-phase-1-yiwei-jiaohuang-ointment-for-gastrointestinal-bleeding-associated-with-oral-antithrombotic-agents-100619079","NCT07339956","Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents","Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Oral therapy with at least one antiplatelet or anticoagulant agent, including: aspirin, clopidogrel, ticagrelor, prasugrel, warfarin, rivaroxaban, apixaban, edoxaban, dabigatran, etc.;\n* BARC stage 1 or 2;\n* Traditional Chinese Medicine pattern identified as phlegm-heat and blood stasis obstruction syndrome;\n* Age 18-90 years;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with gastrointestinal bleeding resulting in hemoglobin levels \\\u003C20 g\u002FL and\u002For requiring hospitalization;\n* Gastrointestinal malignancies;\n* Cases where the source of occult blood cannot be distinguished, such as fresh bleeding from hemorrhoids;\n* Concurrent use of hemostatic traditional Chinese medicine preparations like Yunnan Baiyao;\n* Significant liver or kidney dysfunction, with ALT, AST, or serum creatinine exceeding three times the upper limit of normal;\n* Pregnant women, women planning pregnancy, or lactating women;\n* Individuals deemed unsuitable for this clinical trial by the investigator.","90 Years",{"count":279,"type":22},[530],"The goal of this clinical trial is to evaluate the clinical efficacy and safety of YiWei Jiaohuang Ointment in treating gastrointestinal bleeding associated with oral antithrombotic therapy. The main question it aims to answer is:\n\nDoes Yiwei JiaoHuang Ointment accelerate the conversion to negative results in fecal occult blood tests among patients with gastrointestinal bleeding associated with antithrombotic therapy? Researchers will compare use rabeprazole alone as routine therapy to see if Yiwei JiaoHuang Ointment can accelerate the conversion to negative results in fecal occult blood tests.\n\nParticipants will ： Take Yiwei JiaoHuang Ointment every day for 2 weeks. Return to the hospital for a fecal occult blood test after 3 days, 1 week, and 2 weeks of medication.",[558],"Gastrointestinal Bleeding",[560,561],"Antithrombotic therapy","Traditional Chinese Medicine","2026-01-23",{"date":564,"type":36},"2026-01-26",{"date":566,"type":22},"2026-01-10",{"date":568,"type":22},"2026-08-30",{"name":42,"class":43},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":576,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":99},"100618754","study-on-the-safety-and-efficacy-of-domestic-single-port-robot-assisted-metabolic-bariatric-surgery-100618754","NCT07335731","Study on the Safety and Efficacy of Domestic Single-Port Robot-Assisted Metabolic Bariatric Surgery.","Inclusion Criteria:\n\n* ①Overweight or obese patients who meet the criteria for metabolic weight loss surgery, with a BMI ≥ 27.5 kg\u002Fm2; ② Patients who understand the purpose of the trial, voluntarily participate in the trial, and sign an informed consent form.\n\nExclusion Criteria:\n\n* ① Patients who cannot tolerate general anesthesia, such as those with severe heart, lung, or liver dysfunction; ② Patients with severe coagulation disorders; ③ Pregnant patients; ④ Patients with concurrent tumors; ⑤ Patients with extensive and severe abdominal adhesions that prevent the establishment of pneumoperitoneum; ⑥ A BMI \\> 50 kg\u002Fm² is a relative contraindication; ⑦ Patients deemed unsuitable for participation in this trial by any other investigator.",{"count":577,"type":22},50,[25],"This study aims to obtain short-term clinical results on the safety and efficacy of single-port robot-assisted metabolic weight loss surgery, and to provide further evidence for the clinical promotion of single-port robot systems.",[59,581],"Robot Surgery","2026-01-12",{"date":584,"type":36},"2026-01-13",{"date":586,"type":36},"2025-07-10",{"date":588,"type":22},"2027-07-30",{"name":42,"class":43},""]